Chemomab Therapeutics Ltd ADR (CMMB) Stock Price, Quote & News

Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therape...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 77 331 0156

Website: www.chemomab.com

Address:

Building 7, Kiryat Atidim, Tel Aviv-Yafo, Israel

Snptrader Mar. 16 at 6:55 PM

$CMMB still a $13M market cap for two potential $1B plus markets (PSC/SSC). FDA aligned on a single phase 3 clinical event study for PSC (no biopsy)- just waiting on final acceptance. Partnership with a big pharma to fund P3 should come shortly after. On the brink of many catalyst over the next few months that could move the shares much high. Once financial risk is removed the market will revalue this company for the potential in front of it($150-$300M market cap)--IMO

0 · Reply

dom3 Mar. 16 at 6:04 PM

$CMMB People buying on the offer without strong bids. Very strange trading indeed.

1 · Reply

dom3 Mar. 16 at 4:59 PM

$CMMB It is true that the volume remains anemic for a stock up almost ten per cent.

0 · Reply

dom3 Mar. 16 at 4:58 PM

$CMMB DLTT has just told everyone to watch out. Exactly what are we watching out for? Don't mind bearish comments if they are attached to some sane commentary but simply mouthing off ominous warnings with no context helps nobody..not even the shorts.

0 · Reply